Center for Cell and Gene Therapy, Baylor College of Medicine
116
14
40
50
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
19.0%
22 terminated/withdrawn out of 116 trials
69.4%
-17.1% vs industry average
0%
0 trials in Phase 3/4
46%
23 of 50 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (116)
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Role: collaborator
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Role: collaborator
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Role: collaborator
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Role: collaborator
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Role: collaborator
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Role: collaborator
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Role: collaborator
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Role: collaborator
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
Role: collaborator
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
Role: collaborator
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Role: collaborator
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Role: collaborator
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Role: collaborator
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Role: collaborator
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Role: collaborator
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Role: collaborator
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Role: collaborator
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Role: collaborator
Vitamin C With Steroids for Gastrointestinal GVHD
Role: collaborator
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Role: collaborator